[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636554":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":46,"collaborators":49,"id":52,"slug":7,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":7,"enrollmentInfo":61,"targetDuration":7,"studyType":64,"phases":7,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Universita degli Studi di Genova","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Andrea Bianconi, MD","CONTACT","+393475805577","andrea.bianconi@unige.it",[15,33],{"facility":16,"status":17,"city":18,"state":19,"zip":20,"country":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"AOU Città della Salute e della Scienza","RECRUITING","Torino","Turin","10126","Italy",{"type":23,"coordinates":24},"Point",[25,26],11.99138,44.88856,{"lat":26,"lon":25},[29],{"name":30,"role":11,"phone":31,"phoneExt":7,"email":32},"Fabio Cofano, Md","0116335427","fabio.cofano@unito.it",{"facility":34,"status":17,"city":35,"state":7,"zip":36,"country":21,"cosmosGeoPoint":37,"geoPoint":41,"contacts":42},"IRCCS Azienda Ospedaliera Metropolitana","Genova","16100",{"type":23,"coordinates":38},[39,40],11.87211,45.21604,{"lat":40,"lon":39},[43],{"name":44,"role":11,"phone":45,"phoneExt":7,"email":13},"Andrea Bianconi","3475805577",{"type":47,"investigatorFullName":44,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Assistant Professor",[50],{"name":51,"class":6},"University of Turin, Italy","100636554",false,"NCT07567196","PET-Guided Resection in High-Grade Gliomas","ResPGlioma: Impact of PET-Guided Resection on Survival in High-Grade Gliomas - A Multicenter Prospective Study","ResPGlioma","Inclusion Criteria:\n\n* age ≥18 years\n* high-grade glioma (WHO grade III\u002FIV) diagnosed on MRI\n* provide written informed consent\n\nExclusion Criteria:\n\n* tumors located in the cerebellum, brainstem, or midline.\n* Patients with medical conditions precluding MRI\n* inability to provide written informed consent\n* secondary high-grade gliomas resulting from malignant transformation of a low-grade glioma\n* other primary malignancy within the past five years","ALL","18 Years",{"count":62,"type":63},100,"ESTIMATED","OBSERVATIONAL","Background: Glioblastoma (GBM) is the most common primary brain tumor in adults, with a poor prognosis despite maximal treatment. Current evidence suggests that supramaximal resection, including non-enhancing FLAIR-hyperintense regions, improves survival. However, the extent of FLAIR resection is often limited by functional constraints and its non-specific nature, as it may represent both tumor infiltration and peritumoral edema. This study explores the role of 18F-DOPA PET in refining supramaximal resection by providing a more specific surgical target beyond contrast-enhancing areas.\n\nObjective: To evaluate the impact of 18F-DOPA PET-guided resection on progression-free survival (PFS) and overall survival (OS) in GBM patients, by comparing outcomes between those undergoing PET-RM integrated resection versus conventional MRI-guided resection.\n\nMethods: ResPGlioma is a multicenter, prospective, non-randomized study conducted at IRCCS Ospedale Policlinico San Martino (Genoa) and AOU Città della Salute e della Scienza (Turin). Patients with newly diagnosed, supratentorial, high-grade gliomas undergo preoperative 18F-DOPA PET and MRI. Surgery follows the principle of maximal safe resection, with postoperative MRI at 48 hours assessing the extent of resection (EOR). To confirm PET resection or non-PET resection status, patients will undergo a postoperative 18F-DOPA PET scan at 30 ± 7 days following surgery, prior to the initiation of chemoradiotherapy. Patients are categorized based on EOR criteria (RANO) and PET volume resection (PET-resection vs. PET non-resection). Statistical analyses include Kaplan-Meier survival curves and regression models to identify prognostic factors.Patients are categorized based on EOR criteria (RANO) and PET volume resection (PET-resection vs. PET non-resection). Statistical analyses include Kaplan-Meier survival curves and regression models to identify prognostic factors.\n\nExpected Outcomes: The authors hypothesize that PET-guided resection improves PFS and OS by enabling a more precise tumor removal beyond contrast-enhancing margins while preserving neurological function. Preliminary data support that PET hypercaptant areas contain viable tumor cells and should be resected. This approach may offer a more accessible yet effective alternative to FLAIR-guided supramaximal resection.",[67,68,69,70],"Glioma Glioblastoma Multiforme","Glioma, High Grade","Glioma Surgery","Positron-Emission Tomography(PET)",[72,73,74],"glioma","glioblastoma","PET","2026-04-27",{"date":77,"type":78},"2026-05-05","ACTUAL",{"date":80,"type":78},"2022-04-01",{"date":82,"type":63},"2029-12-31",{"name":5,"class":6},2]